Phase I trial demonstrates high sensitivity of a BCMA-targeting nanobody PET tracer in multiple myeloma, highlighting a shift toward target-specific cancer imaging.
Multiple myeloma is a systemic and spatially heterogeneous cancer of plasma cells. Available methods for diagnosing and monitoring disease do not fully capture its heterogeneity. For instance, bone marrow sampling is anatomically limited and [ 18 F]FDG PET/CT reflects glucose metabolism rather than a specific target. In this issue of JCI , Gu et al. reported a prospective phase I study of [ 68 Ga]Ga-PFBC01, a nanobody tracer targeting B cell maturation antigen (BCMA). The study presents a coherent translational pathway for [ 68 Ga]Ga-PFBC01 PET and demonstrates high sensitivity, associations with tissue and circulating disease measures, and clinical management impact. By shifting myeloma imaging from metabolic assessment toward target biology, [ 68 Ga]Ga-PFBC01 PET may visualize whole-body disease distribution and actionable target expression, while blood-pool activity may reflect systemic antigen biology (Figure 1).
No takes yet. Share an insight, caveat, or question.
Song et al. (2026) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: